| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/NRNEPH.2010.85 |
| P698 | PubMed publication ID | 20606628 |
| P50 | author | Véronique Frémeaux-Bacchi | Q30003568 |
| Matthew C Pickering | Q55692581 | ||
| P2093 | author name string | H Terence Cook | |
| Fadi Fakhouri | |||
| Laure-Hélène Noël | |||
| P2860 | cites work | Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice | Q24651118 |
| Dense deposit disease: a variant of membranoproliferative glomerulonephritis | Q28144476 | ||
| Familial membranoproliferative glomerulonephritis type III | Q28207671 | ||
| Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1 | Q28215804 | ||
| Dense deposit disease is not a membranoproliferative glomerulonephritis | Q28295719 | ||
| Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis | Q28308123 | ||
| Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis | Q29544015 | ||
| Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome | Q33372850 | ||
| Complement regulatory genes and hemolytic uremic syndromes | Q33376289 | ||
| Where next with atypical hemolytic uremic syndrome? | Q33376484 | ||
| Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. | Q33378236 | ||
| Complement and the atypical hemolytic uremic syndrome in children. | Q33380163 | ||
| Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients | Q33381183 | ||
| Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway | Q33403738 | ||
| Membranoproliferative glomerulonephritis | Q33920373 | ||
| Continuing C3 breakdown after bilateral nephrectomy in patients with membrano-proliferative glomerulonephritis | Q34057909 | ||
| Systemic lupus erythematosus, complement deficiency, and apoptosis | Q34082803 | ||
| Membranoproliferative glomerulonephritis type II (dense deposit disease): an update | Q36084453 | ||
| New approaches to the treatment of dense deposit disease | Q36860946 | ||
| Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B | Q37132696 | ||
| Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. | Q37486571 | ||
| Therapeutic potential of complement modulation | Q37644190 | ||
| The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity | Q39968584 | ||
| Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis | Q40144637 | ||
| Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN) | Q40932039 | ||
| The amplification loop of the complement pathways. | Q52704996 | ||
| A mutant complement factor H-related 5 protein is associated with familial C3 glomerulonephritis | Q57608109 | ||
| Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease | Q69505574 | ||
| Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2 | Q73947390 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 494-499 | |
| P577 | publication date | 2010-07-06 | |
| P1433 | published in | Nature Reviews Nephrology | Q2079275 |
| P1476 | title | C3 glomerulopathy: a new classification | |
| P478 | volume | 6 |
| Q35809292 | A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H |
| Q92702921 | A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease |
| Q36050943 | A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. |
| Q44309387 | A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl |
| Q38783519 | A rare case: childhood-onset C3 glomerulonephritis due to homozygous factor H deficiency |
| Q36426921 | Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice |
| Q56908029 | Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies |
| Q38186081 | Acute diffuse proliferative post-infectious glomerulonephritis in renal allograft--a case report and literature review |
| Q36057084 | Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency |
| Q51730313 | An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. |
| Q37632326 | Atypical Plasmacytic Proliferation in a Case of C3 Glomerulopathy: Pathophysiology Demystified |
| Q61807022 | Autoantibodies Against C3b-Functional Consequences and Disease Relevance |
| Q28282953 | Bacterial infection-related glomerulonephritis in adults |
| Q58795472 | Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases |
| Q38763327 | Biologics for the treatment of autoimmune renal diseases. |
| Q58586428 | Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy |
| Q40743490 | C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum |
| Q37644173 | C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo. |
| Q38057737 | C3 glomerulonephritis and CFHR5 nephropathy |
| Q35618793 | C3 glomerulonephritis associated with monoclonal gammopathy: a case series. |
| Q33595318 | C3 glomerulonephritis in multiple myeloma: A case report and literature review |
| Q48309420 | C3 glomerulonephritis with a severe crescentic phenotype. |
| Q34295006 | C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up |
| Q39207807 | C3 glomerulopathy |
| Q40439038 | C3 glomerulopathy and current dilemmas. |
| Q36891110 | C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation |
| Q37426966 | C3 glomerulopathy: clinicopathologic features and predictors of outcome |
| Q37348685 | C3 glomerulopathy: consensus report |
| Q33434161 | C3 mesangial proliferative glomerulonephritis initially presenting with atypical hemolytic uremic syndrome: a case report |
| Q42246527 | C3 nephritic factor associated with C3 glomerulopathy in children |
| Q64938996 | C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases. |
| Q43196981 | C4d Staining in the Diagnosis of C3 Glomerulopathy |
| Q30274884 | C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy |
| Q35584845 | CD11b is protective in complement-mediated immune complex glomerulonephritis |
| Q87393379 | Chapter 8: Idiopathic membranoproliferative glomerulonephritis |
| Q34427591 | Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. |
| Q35246525 | Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience |
| Q49920624 | Clusters Not Classifications: Making Sense of Complement-Mediated Kidney Injury |
| Q30415634 | Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis |
| Q58580445 | Complement C3 Produced by Macrophages Promotes Renal Fibrosis via IL-17A Secretion |
| Q28263460 | Complement System Part II: Role in Immunity |
| Q92420064 | Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions |
| Q26829790 | Complement cascade and kidney transplantation: The rediscovery of an ancient enemy |
| Q26851489 | Complement factor H related proteins (CFHRs) |
| Q33396948 | Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance |
| Q38155653 | Complement in ANCA-associated vasculitis |
| Q40986583 | Complement in Non-Antibody-Mediated Kidney Diseases. |
| Q38226479 | Complement modulation in solid-organ transplantation. |
| Q47108030 | Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways |
| Q89447938 | Concurrent anti-neutrophil cytoplasmic antibody-associated glomerulonephritis and IgG4-associated tubulointerstitial nephritis with C3 glomerulonephritis: A case report |
| Q38843499 | Current status of pediatric renal transplant pathology |
| Q37286653 | Dense deposit disease and C3 glomerulopathy |
| Q92435096 | Dense deposit disease: a greatly increased biopsy incidence in India versus the USA |
| Q48021297 | Diagnostic accuracy of immunofluorescence versus immunoperoxidase staining to distinguish immune complex-mediated glomerulonephritis and C3 dominant glomerulopathy |
| Q40929194 | Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis |
| Q97646109 | Diverse Clinical Presentations of C3 Dominant Glomerulonephritis |
| Q35597310 | Eculizumab and recurrent C3 glomerulonephritis |
| Q24632330 | Eculizumab for dense deposit disease and C3 glomerulonephritis |
| Q36123605 | Eculizumab in Pediatric Dense Deposit Disease |
| Q87166523 | Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy |
| Q42392710 | Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis |
| Q57211731 | Effectiveness of mycophenolate mofetil in C3 glomerulonephritis |
| Q90496015 | Emerging immunotherapies for autoimmune kidney disease |
| Q38991026 | Endothelial cells: source, barrier, and target of defensive mediators |
| Q47918585 | Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy |
| Q64076082 | Factor B and C4b2a Autoantibodies in C3 Glomerulopathy |
| Q50596770 | Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B. |
| Q35030648 | Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees |
| Q55361095 | Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report. |
| Q58110858 | Fukushima journal of medical science original articles re-revised-manuscript No-2018-05 predictive factors for poor outcome in pediatric C3 glomerulonephritis |
| Q50100348 | Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R. |
| Q38123661 | Heparin/heparan sulphate interactions with complement--a possible target for reduction of renal function loss? |
| Q38275117 | Histopathology of MPGN and C3 glomerulopathies |
| Q36890935 | Human C3 glomerulopathy provides unique insights into complement factor H-related protein function |
| Q38026540 | Idiopathic membranoproliferative glomerulonephritis: does it exist? |
| Q38682243 | Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective? |
| Q41431594 | Incidence and profile of C3 Glomerulopathy: A single center study |
| Q90094284 | Infection-related Glomerulonephritis and C3 Glomerulonephritis - Similar Yet Dissimilar: A Case Report and Brief Review of Current Literature |
| Q36438860 | Kidney diseases caused by complement dysregulation: acquired, inherited, and still more to come |
| Q42749819 | Kidney transplant outcomes in familial C3 glomerulopathy |
| Q86932651 | Likely Recurrence of C3 Glomerulonephritis in Kidney Transplantation: An Entity to Bear in Mind: Case Report |
| Q55401948 | Long-term Eculizumab Therapy in a Child With Refractory Immune Complex-Mediated Membranoproliferative Glomerulonephritis. |
| Q36509318 | Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency |
| Q38121480 | Making sense of the spectrum of glomerular disease associated with complement dysregulation |
| Q27008508 | Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion |
| Q38577473 | Membranoproliferative glomerulonephritis and x-linked agammaglobulinemia: an uncommon association. |
| Q37832243 | Membranoproliferative glomerulonephritis with isolated C3 deposits: case report and literature review |
| Q38138908 | Molecular genetics of familial hematuric diseases |
| Q91862977 | Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis |
| Q26864381 | Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging |
| Q64039347 | Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations |
| Q36466296 | New classification of membranoproliferative glomerulonephritis: a good start but a long way to go. |
| Q37658483 | Novel biomarkers in glomerular disease |
| Q33395774 | Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura? |
| Q38101450 | Novel roles of complement in renal diseases and their therapeutic consequences |
| Q35567846 | Pathogenesis of glomerular haematuria. |
| Q38048606 | Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. |
| Q42116082 | Pathology after eculizumab in dense deposit disease and C3 GN. |
| Q44886223 | Positive C1q staining associated with poor renal outcome in membranoproliferative glomerulonephritis |
| Q36689191 | Post-infectious glomerulonephritis with crescents in adults: a retrospective study |
| Q33849695 | Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement |
| Q38118454 | Properdin in complement activation and tissue injury |
| Q40658779 | Protracted Clinical Course of Postinfectious Glomerulonephritis in a Previously Healthy Child |
| Q43086742 | Reanalysis of membranoproliferative glomerulonephritis patients according to the new classification: a multicenter study |
| Q38088187 | Recent insights into C3 glomerulopathy |
| Q26741542 | Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN |
| Q40840681 | Recovery of renal function succeeding stem cell transplant: a case of C3 Glomerulonephiritis secondary to monoclonal gammopathy |
| Q34467879 | Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant |
| Q47193282 | Recurrence of primary glomerulonephritis: Review of the current evidence |
| Q93047764 | Recurrent and de novo Glomerulonephritis After Kidney Transplantation |
| Q33439122 | Recurrent atypical haemolytic uraemic syndrome post kidney transplant due to a CD46 mutation in the setting of SMARCAL1-mediated inherited kidney disease |
| Q54267107 | Recurrent postinfectious glomerulonephritis: an unusual evolution compatible with C3 glomerulopathy. |
| Q57945954 | References |
| Q35532337 | Regulating complement in the kidney: insights from CFHR5 nephropathy |
| Q38749961 | Retinal disease in the C3 glomerulopathies and the risk of impaired vision. |
| Q47142300 | Retinal findings in membranoproliferative glomerulonephritis. |
| Q64050925 | Rituximab fails where eculizumab restores renal function in C3nef-related DDD |
| Q38749694 | Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies |
| Q34514835 | Successful management of a patient with a C3 Glomerulonephritis and crescentic pattern: a case report |
| Q41599462 | Successful treatment of infectious endocarditis associated glomerulonephritis mimicking c3 glomerulonephritis in a case with no previous cardiac disease |
| Q36320011 | The C5a receptor has a key role in immune complex glomerulonephritis in complement factor H-deficient mice |
| Q83477877 | The absence of immunoglobulin D B cell receptor-mediated signals promotes the production of autoantibodies and exacerbates glomerulonephritis in murine lupus |
| Q86017361 | The author replys: |
| Q38137749 | The immune system and kidney disease: basic concepts and clinical implications. |
| Q84795502 | The many faces of C3 glomerulopathy |
| Q38062343 | The renal biopsy in the genomic era. |
| Q49947954 | The role of the alternative pathway of complement activation in glomerular diseases |
| Q33396467 | Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. |
| Q38394841 | Toward a working definition of C3 glomerulopathy by immunofluorescence |
| Q35624672 | Treatment options for C3 glomerulopathy |
| Q38880897 | Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies |
| Q33403607 | Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies |
| Q92435101 | Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy |
| Q93064481 | Utility of immunohistochemistry with C3d in C3 glomerulopathy |
Search more.